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Abstract
We study the correlation of the occurrence of coronary heart disease (CHD) with the presence of
the single-nucleotide polymorphism (SNP) at the -308 position of the tumor necrosis factor alpha
(TNF-α) gene. We also consider the influence of the occurrence of type 2 diabetes (t2DM). Using
Bayesian inference, we first pursue a bottom-up approach to compute the working hypothesis and
the probabilities derivable from the data. We then pursue a top-down approach by modelling
the signal pathway that causally connects the SNP with the emergence of CHD. We compute the
functional form of the probability of CHD conditional on the presence of the SNP in terms of both
the statistical and biochemical properties of the system. From the probability of occurrence of
a disease conditional on a given risk factor, we explore the possibility of extracting information
on the pathways involved in the occurrence of the disease. This is a first study that we want
to systematise into a comprehensive formalism to be applied to the inference of the mechanism
connecting the risk factors to the disease.
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I. INTRODUCTION
We are interested in the association of diseases, in particular of coronary heart disease
(CHD), with genetic factors in order to determine underlying genetically-driven functional
mechanisms that are causally related to the disease. In this context, environmental factors
are regarded as contaminants. Among the risk factors for the emergence of CHD, genetic
determinants may provide a wealth of information on the nature of the disease, which can
be used to develop new diagnosis and treatment methods. The study of these factors has
attracted the effort of many research teams for the identification of disease susceptibility
genes as well as acquired somatic mutations. Among these genes is that of the tumor
necrosis factor alpha (TNF-α), a pleiotropic cytokine produced mainly by macrophages and
T-cells which is involved in the inflammatory response of the immune system [1].
It has been suggested that the TNF-α gene affects the modulation of lipid metabolism,
obesity susceptibility, and insulin resistance [2–4], thus being potentially implicated in the
development of cardiovascular diseases (see Ref. [5] and references therein). Several single-
nucleotide polymorphisms (SNPs) have been identified in the human TNF-α [6, 7]. The best
documented of these SNPs are at position -308 of the TNF-α gene promoter. It involves
the substitution of guanine (G) for adenine (A) and the creation of two alleles, TNF1(A)
and TNF2(G), and three genotypes, GG, GA and AA [8]. There is evidence implicating
TNF-α in an increased susceptibility to the pathogenesis of a variety of diseases (see Ref. [4]
and references therein). However, the results on its association with CHD are contradictory,
some implying different influence of the two alleles on the prevalence of CHD [3, 4], others
implying no association [9–12]. This conflict is due in part to the results being based on the
frequentist analysis [13].
In order to infer the risk of CHD derived from potential risk factors, it is important
to develop a formalism that extracts all possible information from the data and combines
them with other data sets on different intervening factors for a consistent inference of the
correlations. Here we introduce a possible formalism based on Bayesian inference and test its
applicability on the three-variable data set from Ref. [2]. In this manuscript we attempt to
quantify the risk of occurrence of CHD based on its association with the SNP at the position
-308 of the TNF-α promoter. This entails the calculation of a probability distribution for
the occurrence of CHD conditional on the SNP or other factors. The influence of other
factors is here illustrated by the occurrence of type 2 diabetes (t2DM).
When, instead of computing the probability distribution of some quantity produced by
the process, we compute the conditional probability of an unsolved variable in the process
given the observed variables, we are solving an inverse probability problem. This requires the
use of the Bayes theorem. The Bayesian approach has been used extensively for parameter
inference and model selection from cosmology [14–16] to biology [17–20] among many others.
In this case, we observe the occurrence of a given disease and the correlation with a SNP. In
the absence of a theory, we relate the SNP with the disease via a model of the potentially
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implicated pathways. The parameters of this model are the relevant factors that we want
to infer from the data. Such a theory would be important as a first step to predict the
occurrence of a genetically-driven disease for a given polymorphism, as well as to understand
the mechanism of genetic mutation from which polymorphisms derive. In this study we
propose a solution to the first problem and will approach the second problem in a forthcoming
study.
The causal relation between the risk factors and the occurrence of the disease is a function
of the rates which characterize the implicated pathways. Here, knowing how the occurrence
of the disease is distributed over the parameter space of the risk factors and knowing how
the risk factors act at the biochemical level, we show how we can extract information on the
pathway involved in the emergence of the disease. However, since the pathways involved are
most likely interconnected with others, sourced by different factors, the next step would be
to allow for the participation of various factors in the emergence of the same disease. There is
a plethora of sparse phenomenological/symptomatic data on the simultaneous occurrence of
SNP’s and diseases from which correlations are tentatively drawn. The formalism developed
here can be extended to other factors in the effort to systematise the sparse data to identify
risk factors, to combine them into a comprehensive model for the mechanism that leads to
the disease and therefrom to infer a universal law of gene mutation.
The manuscript is organized as follows. In section II we select the working hypothesis for
the relation between the SNP and CHD on the basis of the Bayes factors and compute the
probabilities in the presence of the SNP derivable from the data. One of these will be used
as the likelihood for the occurrence of CHD. In section III we suggest a simplistic model
for the signalling pathway between the onset of the SNP and the emergence of CHD, and
compute the posterior probability for the occurrence of CHD. Finally we comment on the
results and indicate the research routes that we will be exploring next.
II. BOTTOM-UP APPROACH
We will base our analysis on the data reported in Ref. [2], which consist of frequencies of
occurrence of CHD as a function of the SNP at the position −308 of the TNF-α promoter.
It is also advanced a correlation between the SNP and an increased predisposition to CHD
in type 2 diabetic patients. That study also comprises an analysis of the gender dependence
on diabetes.
The sample of CHD patients consists of NCHD = 341 randomly selected patients. Out of
these, NCHD,t2DM = 106 also suffered from t2DM. Another sample of type 2 diabetic patients
numbering NCHD,t2DM = 135 was selected among non-CHD patients. These two samples,
together with a control sample of NCHD,t2DM = 207 non-CHD non-diabetic patients, were
analysed for the occurrence of the −308 TNF-α SNP. Thus the total number of diabetic
patients consists of a random and a non-random component on the factor CHD. Since we
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CHD CHD
t2DM t2DM t2DM t2DM
SNP 43 67 26 48
SNP 63 168 109 159
Table I: The data. Frequencies of the TNFα–308 SNP in CHD patients, t2DM patients and
controls.
are interested in studying the correlation between the SNP and CHD, we cannot use the
data on the sample of non-CHD diabetic patients to extract information on the frequency
of occurrence of CHD given that diabetes had occurred, because the information would be
biased. We can, however, derive information on the frequency of diabetes given that the
SNP or CHD occurred. The data are summarized in Table I.
A. Model comparison: the Bayesian evidence
Given the data, we can derive the influence of CHD and t2DM on the SNP. We have three
variables, namely occurrence of CHD (CHD), occurrence of t2DM (t2DM) and presence
of the SNP (SNP ), and six hypotheses for the presence of the SNP. The hypotheses are
the following: H00: the probability of the SNP does not depend on the occurrence of either
CHD or t2DM; H01: the probability of the SNP depends on the occurrence of CHD; H10:
the probability of the SNP depends on the occurrence of t2DM; H11: the probability of the
SNP depends on the independent occurrence of both CHD and t2DM; Hchd11 : the probability
of the SNP depends on the occurrence of CHD and on the occurrence of t2DM given that
CHD is present; H t2dn11 : the probability of the SNP depends on the occurrence of t2DM and
on the occurrence of CHD given that diabetes is present. These are schematically depicted
in Fig. 1
We note that, given the selection criterion for the population of NCHD,t2DM , we cannot use
the corresponding data to infer on the occurrence of CHD given the occurrence of t2DM since
they would bias the results. For this reason, H t2dm11 is excluded as a viable hypothesis given
the data collected. We proceed to compare the remaining hypotheses based on Bayesian
evidence. The probability of an hypothesis given the data is the posterior probability of the
corresponding model [21]
P (Hi|D) = P (D|Hi)P (Hi)
P (D)
(1)
where P (D|Hi) is the evidence, P (Hi) is the prior probability of Hi and P (D) =∑
i P (D|Hi)P (Hi). In order to infer which hypothesis is more likely in view of the data,
we compare the evidence computed for the alternative hypotheses. The evidence is the
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CHD CHDCHD t2DMt2DM t2DM
SNP SNPSNP
H00 H01 H10
CHD CHD CHDt2DM
SNP
t2DM
SNP SNP
t2DM
H11 H
chd
11 H
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Figure 1: Diagram of the hypotheses considered. The circles denote the corresponding
variables. The arrows denote a correlation between the encircled variables which they connect. A
straight arrow indicates that the probability of the variable at the tip of the arrow is conditional
on the variable at the origin of the arrow. A curved arrow indicates that the probability of the
variable at the tip of the arrow is conditional on the variable at the inflection of the arrow, which
moreover is conditional on the variable at the origin of the arrow. In the upper set we have H00,
H01 and H10; in the lower set we have H11, H
chd
11 and H
t2dm
11 .
integral of the likelihood over the parameter space θ of the model
P (D|Hi) =
∫
dθP (D|θ ∧Hi)P (θ|Hi). (2)
Assuming equal prior probabilities for the different hypotheses, then
P (Hi|D)
P (Hj|D) =
P (D|Hi)
P (D|Hj) . (3)
We compute the evidence for the five hypotheses described above (for details see Appendix
A). In order to compare the hypotheses, we take the logarithm of the ratio of the corre-
sponding evidences, P (Hi|D)/P (Hj|D) = Bij, which we present in Table II. This quantity
is known as the Bayes factor and gives empirical levels of significance for the strength of
the evidence. It also encapsulates Occam’s factor which measures the adequacy of the
hypothesis to the data over the parameter space of the hypothesis [21]. The levels of sig-
nificance ascribed to the Bayes factor are calibrated by the Jeffrey’s scale [22] as follows: if
1.0 < Bij < 3.2, Hi should not be favoured over Hj; if 3.2 < Bij < 10, there is substantial
evidence for Hi over Hj; if 10 < Bij < 100 there is strong evidence, while for Bij > 100
the evidence for Hij should be considered decisive. In the first column, we find the Bayes
factors which relate each hypothesis with H00. Since hypothesis H00 describes the data as
the result of a random process, this column measures the preference for a departure from
randomness [23]. From these values we infer that all hypotheses are substantially favoured
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Brow,col H00 H01 H10 H11 H
chd
11
H00 0
H01 3.99 0
H10 4.37 0.91 0
H11 4.08 1.02 0.93 0
Hchd11 7.07 1.77 1.62 1.73 0
Table II: The Bayes factors for the hypotheses considered. Here Brow,col = Hrow/Hcol.
over H00. The values seem to suggest that H
chd
11 is also favoured over the other hypotheses,
however they are not sufficient to infer substantial evidence. Since Hchd11 is the hypothesis
that exhibits the most substantial evidence over the null hypothesis (this hypothesis was
supported in Ref. [2] with p = 0.0056), we will take Hchd11 as our working hypothesis upon
which we will base our subsequent inferences.
B. Model fitting
Having inferred from the computation of the evidence which of the possible hypotheses
is most likely to be compatible with the data in the presence of the SNP, we proceed to
compute the probability for the occurrence of the polymorphism. Let H denote our working
hypothesis. Then the probability that the SNP is present is
P (SNP |H) =
∫
dθ P (SNP |θ)P (θ|D ∧H) =
∫
dθ P (SNP |θ)P (D|θ ∧H)P (θ|H)
P (D|H) . (4)
Since Hchd11 consists of a two-component hypothesis [24], each of which described by two
parameters, the resulting parameter space is four-dimensional. The equation above must be
generalized for a multidimensional parameter space where each factor is no longer a scalar
but instead a (4x4) matrix. Since each component consists of two disjoint sets, the matrix
is diagonal, each component being weighted by the relative size of the population. We then
write
P (SNP |H) =
∫
d2p P (SNP |p)P (p|D ∧H) +
∫
d2p¯ P (SNP |p¯)P (p¯|D ∧H). (5)
Here the indices range over the two-dimensional parameter spaces, with p = (p01, p11) and
p¯ = (p01¯, p1¯1), where for simplicity we have dropped the tilde from the notation used in
Appendix A. In particular, p01 is the frequency of SNP given the occurrence of CHD and
p01¯ the frequency of SNP given non-occurrence of CHD, both subject to non-occurrence
of t2DM, whereas p11 is the frequency of SNP given that t2DM has occurred and p1¯1 the
frequency of SNP given that t2DM has not occurred, both subject to CHD having occurred.
Let P (SNP |p) = p and P (SNP |p¯) = p¯. The posterior probability of p is by the Bayes
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theorem
P (p|D ∧H) = P (D|p ∧H)P (p|H)
P (D|H) =
P (D|p ∧H)
P (D|H) (6)
and similarly for the posterior probability of p¯. In the last step we assume for simplicity a
uniform prior for both p and p¯.1 Writing the evidence as
P (D|H) =
∫
d2p P (D|p ∧H)P (p|H) +
∫
d2p¯ P (D|p¯ ∧H)P (p¯|H) (7)
we find for hypothesis Hchd11 that
P (SNP |H) =
=
1
P (D|H)
∫
dp01
∫
dp11
∫
dp01¯
∫
dp11¯
×
[
γ
(
NCHD,t2DN
NSNP,CHD,t2DN
)
p
NSNP,CHD,t2DN+1
01 (1− p01)NSNP,CHD,t2DN
+(1− γ)
(
NCHD,t2DN
NSNP,CHD,t2DN
)
p
NSNP,CHD,t2DN+1
11 (1− p11)NSNP,CHD,t2DN
+γ˜
(
NCHD,t2DN
NSNP,CHD,t2DN
)
p
NSNP,CHD,t2DN+1
01¯
(1− p01¯)NSNP,CHD,t2DN
+(1− γ˜)
(
NCHD,t2DN
NSNP,CHD,t2DN
)
p
NSNP,CHD,t2DN+1
1¯1
(1− p1¯1)NSNP,CHD,t2DN
]
(8)
which yields
P (SNP |H) = 1
P (D|H)
×
[
γ
NSNP,CHD,t2DN + 1
(NCHD,t2DN + 2)(NCHD,t2DN + 1)
+(1− γ) NSNP,CHD,t2DN + 1
(NCHD,t2DM + 2)(NCHD,t2DM + 1)
]
+γ˜
NSNP,CHD,t2DN + 1
(NCHD,t2DN + 2)(NCHD,t2DN + 1)
+(1− γ˜) NSNP,CHD,t2DN + 1
(NCHD,t2DM + 2)(NCHD,t2DM + 1)
]
. (9)
Here γ = NCHD,t2DM/NCHD and γ˜ = NCHD,t2DM/Nt2DM , with P (D|H) given by Eqn. (A9).
Substituting the values from Table I we find that P (SNP |H) = 0.30 ± 0.001, which we
identify as the effective mutation rate λeff of the Poisson probability distribution describing
the occurrence of the SNP. Although comparable, this value is different from the na¨ıve guess
1 This choice of prior is justified by the absence of an a priori bias on the values of these parameters.
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λ = NSNP/N = 0.27 or from the more elaborate one arising from the assumption of the null
hypothesis [see Appendix B for the derivation]. It then follows that the posterior probability
for the occurrence of n mutations in a population of size N is
P (n|λeff ∧N) = exp[−λeffN ] (λeffN)
n
n!
. (10)
Similarly we compute
P (SNP |CHD ∧H) =
∫
d2p P (SNP |CHD ∧ p)P (p|D ∧H) =
∫
d2p
p P (D|p ∧H)
P (D|H)
=
1
P (D|H)
[
γ
NSNP,CHD,t2DN + 1
(NCHD,t2DN + 2)(NCHD,t2DN + 1)
+(1− γ) NSNP,CHD,t2DN + 1
(NCHD,t2DM + 2)(NCHD,t2DM + 1)
]
(11)
and find that P (SNP |CHD ∧H) = 0.20± 0.001. We can also compute
P (t2DN |CHD ∧H) =
∫
dp P (t2DM |CHD ∧ p)P (p|D ∧H)
=
1
P (D|H)
NCHD,t2DN + 1
(NCHD + 2)(NCHD + 1)
(12)
finding that P (t2DN |CHD ∧H) = 0.09± 0.001. The errors indicated were computed from
error propagation, assuming the error of a counting result n to be 1/
√
n.
III. TOP-DOWN APPROACH
We now proceed to estimate the influence of the SNP on the occurrence of CHD. We
want to find the posterior probability of the occurrence of CHD given the presence of the
SNP, i.e.
P (CHD|SNP ∧H) = P (SNP |CHD ∧H)P (CHD|H)
P (SNP |H) . (13)
Here P (CHD|H) is the prior probability of CHD and P (SNP |CHD ∧H) is the likelihood
of CHD for a fixed SNP. The remaining term P (SNP |H) has no CHD dependence and
can thus be absorbed into the normalization constant. It is known as the evidence or the
marginal likelihood.
A. A simplistic model for the signalling pathway
Since the working hypothesis relates the presence of the SNP with both the occurrence
of CHD and the occurrence of t2DM, we infer that the changes from the canonical pathway
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(a) x0 y0
α
(0)
xx α
(0)
xy
x1
α
(1)
xx α
(1)
yx
x2 y2
xˆ0 y0
α
(0)
xx α
(0)
xyα
(0ˆ)
xy
xˆ1
α
(1)
xx α
(1)
yx
xˆ2 yˆ2
(b) x0 y0
α
(0)
xx α
(0)
yy
x1 y1
α
(1)
xx α
(1)
yy
x2 y2
xˆ0 y0
α
(0)
xx
α
(0ˆ)
xy
α
(0)
yy
xˆ1 yˆ1
α
(1)
xx α
(1)
yy
xˆ2 yˆ2
Figure 2: Diagram of the pathways with different source signals. The first column depicts
the original architecture corresponding to the canonical pathway (i.e., in the absence of the SNP).
The second column depicts one possible alteration of the corresponding pathway due to the SNP.
Here the SNP acts on the signal x0. The continuous lines represent the functioning pathways, and
the dashed lines represent pathways which can suffer delay or cease to function entirely (in the case
of previously existing pathways), or which could simply not come to exist (in the case of newly
generated pathways). (a) Case 1a). For y0 = 0 this reduces to Case 2. (b) Case 1b).
introduced by the SNP will have repercussions on the signalling cascades which regulate the
emergence of CHD and t2DM. If we assume that the SNP will only affect one source signal,
then this correlation suggests that the resulting signal transduction pathways interfere with
one another. Functional interference can be derived from a common source signal or from
common components downstream [25, 26]. As far as the source signal is concerned, we allow
for two possibilities: 1) the pathways have different source signals; 2) the pathways have the
same source signal and sufficiently downstream diverge. In case 1) and in order to reproduce
interference between the two signalling pathways we can still have two further sub-cases: 1a)
the pathways share components and the effect of the SNP consists of either an alteration in
the velocity of the affected signal or an alteration of one of the pathways; 1b) the pathways
do not share components but the pathway altered by the SNP shares components with the
unaltered one. These two subcases can be distinguished by the correlation between the two
diseases in the absence of the SNP, with case 1a) describing the existence of an a priori
correlation between the occurrence of the two diseases and case 1b) the absence of such
correlation. In case 2) the interference is built-in so the effect of the SNP is similar to that
in case 1a). The diagrams are depicted in Fig. 2 which we proceed now to describe.
The variables x and y describe black boxes along the pathways that regulate the emergence
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of CHD and t2DM respectively. By black boxes we mean unresolved chemical reactions
where no intervening elements are specified other than the input and the output reaction
rates between two sequential black boxes. The index of the variables denotes the relative
position in the pathway of the corresponding black box component. Thus ’0’ indicates the
upstream component fed by the initial signal and which is subject to alteration upon the
action of the SNP, whereas ’2’ indicates the final component which determines the emergence
of the disease, with ’1’ denoting the intermediary component where the interference of the
altered pathway with the unaltered one is manifested. Here the SNP affects the signal x0
and propagates downstream through an altered or newly created pathway ’0ˆ’. A variable
which refers to an altered pathway is denoted by xˆ0, whereas a variable which refers to a
newly created pathway is denoted by x0ˆ. The same rule holds for the corresponding rates.
The cases where the original pathway ceases to function can be interpreted as inhibition.
This a simplistic description of the potential signalling pathways involved, which is but a
caricature of the real biochemical system. Nonetheless it is the possible description based
on the data, which moreover captures the functional correlations inferred.
To select the working model we use as criterion the possibility of the emergence of a
connection between the SNP and each disease without the participation of the other. We
conceive three possible ways for the SNP to function: (1) the signal does not suffer any
alteration from that in the absence of the SNP; (2) the signal is triggered at a smaller rate
so that xˆ0 < x0; (3) no signal is triggered. We can exclude (1) on the basis that it contradicts
the working hypothesis. Moreover, since (3) can be described as a limiting case of (2) when
xˆ0 = 0, we proceed to solely analyse (2) with each suggested model according to the disease
combinations which can be reproduced.
Case 1a) If both x2 and y2 require that x1 be acted by the products of both x0 and
y0, then the functional time scales of the two pathways should be very close. In the case
of a slower reaction rate, if the signalling pathways are assumed to consist of an isolated
system then both diseases would occur. The way to prevent it would be by capturing the
required reagents from neighbouring pathways. This scenario, however, would be beyond
our current capabilities of inference and constraint. If instead x1 has the flexibility of being
independently activated by the two signals and of also independently acting upon x2 and
y2, then the emergence of the diseases will depend on the supply of each pathway that
develops from x1 downstream. Should a single triggering signal be enough to supply for both
downstream pathways, it could be the case that no disease occurs. This would moreover
depend on the phase difference between the generation of x1 upon the activation of x0 and
y0. Should one triggering signal not be enough, then either disease could occur. This could
be prevented if a compensation mechanism were triggered so that, in the absence of an
effective signalling from one source, the working source would be stimulated according to
the deficiency.
Case 1b) In this case, x1 and y1 are independently sourced and independently develop
their pathways downstream. In the case of a slower reaction rate, no interference would be
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generated as long as the SNP-affected pathway could still run. However, in the case of a
more drastic reduction of the trigger of x1, an alternative pathway would be intercepted and
the required reagents deviated. This could lead to a case of competition. Should pathway
x be thus maintained, pathway y could either collapse or continue, resulting in the disease
implicated in the pathway y emerging or not. If pathway x cannot be maintained and the
corresponding disease is not avoidable, then we can still have either emergence or not of the
other disease, depending on the degree of reagent deviation.
This empirical analysis can be complemented by the following quantitative one. We will
assume that the system under study can be described as a dynamical one. In the absence of
the SNP, the dynamical system is described by the rates indicated in Fig. 2, first column. If
the SNP has occurred in the coding of the input signal in x0, then the system will instead be
sourced by the altered xˆ0 and described by the rates as indicated in Fig. 2, second column.
We compute the fixed points (identified by the superscript ’∗’) of the quantities involved
in both the canonical pathway and the SNP–altered one. The fixed points describe the state
of the system in dynamical equilibrium and are computed by setting the time derivates equal
to zero. Since we are interested in the probabilities which describe the average states of the
system and not in the dynamical evolution that leads to those states, the fixed points are
the variables to be used.
For case 1a)
dxˆ1
dt
= α(0)xx xˆ0 +
[
α(0)xy + α
(0ˆ)
xy β(xˆ0)
]
y0 −
(
α(1)xx + α
(1)
yx + δ
(1)
x
)
xˆ1 (14)
dxˆ2
dt
= α(1)xx xˆ1 − δ(2)x xˆ2 (15)
dyˆ2
dt
= α(1)yx xˆ1 − δ(2)y yˆ2 (16)
where the δ’s denote decay rates. Here β is the fraction of the output of y0 which activates
x1 and thereby attempts to compensate for the deficiency of activation of x1 derived from
the SNP
β(xˆ0) =
(
1− xˆ0
x0 −∆thres0
)
Θ[x0 −∆thres0 − xˆ0] (17)
where Θ is the Heaviside step function. This term is reminiscent of the carrying capacity term
which sets an upper limit to cellular growth [27]. Here we set a lower limit, as determined by
∆thres0 , to the deficiency in x0 caused by the altered signal for the onset, as imposed by the
step function, of the compensating mechanism. This quantity would measure a functional
marker for the presence of the SNP. We compare the fixed points in both the canonical
pathway and the SNP-altered one, finding that
xˆ∗2 − x∗2 =
[
α(0)xx (xˆ0 − x0) + α(0ˆ)xy β(xˆ0)y0
] α(1)xx
δ
(2)
x
1
α
(1)
xx + α
(1)
yx + δ
(1)
x
(18)
yˆ∗2 − y∗2 =
[
α(0)xx (xˆ0 − x0) + α(0ˆ)xy β(xˆ0)y0
] α(1)yx
δ
(2)
y
1
α
(1)
xx + α
(1)
yx + δ
(1)
x
. (19)
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This shows that, in the absence of the compensating term in y0, a difference in x0 will be
reflected in a difference in both x∗2 and y
∗
2, and thus imply the occurrence respectively of CHD
and diabetes. Thus the occurrence of each disease will be related to both the onset of the
altered signal and to the change from the canonical pathway of its propagation downstream.
Expressing xˆ0 and yˆ
∗
2 as functions of xˆ
∗
2, we find that
xˆ0 =
1
A0
(A2xˆ
∗
2 − A) (20)
yˆ∗2 =
xˆ∗2
B2
(21)
where the A’s and B’s are functions of the biochemical rates, the canonical signal x0 and
the fixed point of the canonical pathway x∗2.
For case 1b)
dxˆ1
dt
= α(0)xx xˆ0 + α
(0ˆ)
xy β(xˆ0)y0 −
(
α(1)xx + δ
(1)
x
)
xˆ1 (22)
dyˆ1
dt
= α(0)yy [1− β(xˆ0)] y0 −
(
α(1)yy + δ
(1)
y
)
yˆ1 (23)
dxˆ2
dt
= α(1)xx xˆ1 − δ(2)x xˆ2 (24)
dyˆ2
dt
= α(1)yy yˆ1 − δ(2)y yˆ2. (25)
The fixed points for the canonical and altered pathways are related as follows
xˆ∗2 − x∗2 =
[
α(0)xx (xˆ0 − x0) + α(0ˆ)xy β(xˆ0)y0
] α(1)xx
δ
(2)
x
1
α
(1)
xx + δ
(1)
x
(26)
yˆ∗2 − y∗2 = −α(0ˆ)yy β(xˆ0)y0
α
(1)
yx
δ
(2)
y
1
α
(1)
yy + δ
(1)
y
. (27)
In this case, the change from the sharing of a component while compensating for the supply
of one pathway could cause the other to be depleted of essential reagents. The outcome,
however, will depend on how much the intercepting pathway takes and how much the inter-
cepted pathway can run canonically without. Similarly we find expressions for xˆ0 and yˆ
∗
2 as
functions of xˆ∗2
xˆ0 =
1
A0
(A2xˆ
∗
2 − A) (28)
yˆ∗2 =
1
B2
[
(A2xˆ
∗
2 − A)
B0
A0
+B
]
(29)
where similarly the A’s and B’s are functions of the biochemical rates, the canonical signal
x0 and the fixed points of the canonical pathways x
∗
2 and y
∗
2.
In the following subsection we will use as the working description of the signalling pathway
the dynamical system of case 1a). Given the similarity in the functional form of the depen-
dence of the variables, similar conclusions would also be inferred, with the interpretation
only differing on the basis of the different structure of the pathways.
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B. Translation of the dynamical system into a probability description
In order to compute P (CHD|SNP∧H), we proceed to write the probabilities in Eqn. (13)
in terms of the variables in the description of the dynamical system. In particular, we want
to compute
P (x2|x0) = P (x0|x2)P (x2)
P (x0)
(30)
where the probability P (x2) is related to that for the occurrence of CHD and the likelihood
P (x0|x2) is related to that for the data on the SNP conditional on the prior for CHD. The
quantity P (x0) is the evidence, which is found by marginalising the likelihood and is related
to the probability for occurrence of the SNP. We will use the probabilities computed in the
previous section to constrain the priors assumed here. We will then derive an expression
for P (CHD|SNP ∧ H) in terms of both the statistical properties of the priors and the
biochemical parameters of the transmission process from the SNP to the CHD.
We assume that the probability for the occurrence of CHD is described by a Gaussian
distribution with expectation value equal to the fixed point of the final component of the
pathway µ2P = x
∗
2, and standard deviation σ2P
P (x2) =
1√
2piσ2P
exp
[
−(x2 − µ2P )
2
2σ22P
]
. (31)
In the probability description, the quantities µ2P and σ2P are properties of the prior knowl-
edge of the distribution of the occurrence of CHD derived from population sampling and
expressed in terms of the biochemical parameters of the system according to the model
considered. In the absence of further data, these quantities characterize a theoretical prior
which we can assume to be approximated by a binomial distribution for sufficiently large
NCHD. The parameter of the binomial distribution is the frequency of occurrence of CHD
which has for maximal likelihood estimator pCHD = NCHD/(NCHD +NCHD). The mean and
the variance of the approximated Gaussian distribution are given by
µ2P = NCHD pCHD, σ
2
2P
= NCHD pCHD(1− pCHD) (32)
which yield respectively µ2P = 170± 1 and σ2P = 9.2± 1.6. The fixed point corresponding
to the canonical pathway denotes absence of disease, whereas deviations from this value
will entail a non-vanishing probability of occurrence of CHD. In order to quantify this
probability, we need to devise a criterion to determine the emergence of CHD. Deviations
on the fixed point of an altered pathway from that of the canonical pathway are quantified
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by ∆2 = µ2P − xˆ∗2.2 This quantity would measure a non-environmental marker3 for the
occurrence of CHD [28]. For deviations larger than a threshold value ∆thres2 the disease will
occur. The probability of occurrence of CHD will be
P (CHD) = P (x2 < µ2P −∆thres2 )
=
1√
2piσ2P
∫ µ2P−∆thres2
−∞
dx2 exp
[
−(x2 − µ2P )
2
2σ22P
]
. (33)
Deviations at the level of x2 will be the result of the propagation along the pathway of devi-
ations at the level of x0 according to Eqn. (18) or (26), depending on the model considered.
The likelihood of the data on x0 given the variable x2 is assumed also to follow a Gaussian
distribution centred at xˆ0 and with standard deviation σ0D [29]
P (xˆ0|xˆ∗2) =
1√
2piσ0D
exp
[
−(xˆ0 − xˆ
∗
2)
2
2σ20D
]
. (34)
Here the quantities xˆ0 and σ0D describe properties of the data in the presence of the SNP
expressed in terms of the biochemical parameters of the system. The likelihood of CHD
will be given by the integral in x2 because the SNP enters as data through the modelling
of the system. Substituting xˆ0 = xˆ0(xˆ
∗
2) = (A2 xˆ
∗
2 − A)/A0, where the A’s are functions of
the statistical parameters µ2P , x0 and σ0D as well as of the biochemical parameters, we find
that
P (SNP |CHD) = 1√
2piσ0D
∫ µ2P−∆thres2
−∞
dxˆ∗2 exp
[
−(xˆ0 − xˆ
∗
2)
2
2σ20D
]
=
1
2
+
A0
2(A0 − A2) erf
[
A+ (µ2P −∆thres2 )(A0 − A2)√
2σ0DA0
]
(35)
where erf stands for the error function given by the integral erf(x) = (2/
√
pi)
∫ x
0
dy exp[−y2].
This probability was computed in Eqn. (11).
We can now derive the functional form of the evidence in terms of the statistical and the
biochemical parameters. Combining the two assumptions above, we find that
P (xˆ0|xˆ∗2)P (xˆ∗2) =
1
2piσ0Dσ2P
exp
[
−1
2
(
Γ− µ2eff
)]
exp
[
−(xˆ
∗
2 − µeff )2
2σ2eff
]
(36)
2 In accordance with the description encapsulated in the model, the SNP will act by causing deficiency
in the modus operandi of the system. Should it instead act by causing excess, then a symmetric interval
about µ2P would be the generalization to account for possible saturation and consequent screening effect.
The changes to implement in all the subsequent results would be straightforward.
3 The distinction between functional and environmental markers can be shady and will thus require care.
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where
µeff =
(
µ2P
σ22P
− xˆ0
σ20D
)/(
1
σ22P
+
1
σ20D
)
, (37)
σ2eff = 1
/(
1
σ22P
+
1
σ20D
)
, (38)
Γ =
(
µ22P
σ22P
+
xˆ20
σ20D
)
. (39)
Substituting xˆ0 = xˆ0(xˆ
∗
2), we integrate in xˆ
∗
2 finding that
P (SNP ) =
∫ +∞
−∞
dxˆ∗2 P (xˆ0|xˆ∗2) P (xˆ∗2)
=
1√
2pi
1√
σ20D + σ
2
2P
(A0 − A2)2/A20
exp
[
−1
2
[A/A0 + µ2P (A0 − A2)/A0]2
σ20D + σ
2
2P
(A0 − A2)2/A20
]
. (40)
If we furthermore assume that x0 follows a Gaussian distribution centred at the value for
the canonical path, which we denote by µ0, and with standard deviation σ0D , which is such
that ∆thres0 =
√
2σ20D ln[1/P (xˆ0)] when xˆ0 = µ0 −∆thres0 , then following a similar reasoning
to that for CHD, we will have presence of the SNP for xˆ0 < µ0 −∆thres0 . Hence
P (SNP ) =
1√
2piσ0D
∫ µ0−∆thres0
−∞
dxˆ0 exp
[
−(xˆ0 − µ0)
2
2σ20D
]
=
1
2
− 1
2
erf
[
∆thres0√
2σ0D
]
(41)
which equals λeff = 0.30± 0.001, as computed in Eqn. (9), and thus serves to constrain the
parameters in Eqn. (40). We can also solve for ∆thres0 finding that ∆
thres
0 = (0.52±0.006)σ0D .
The quantity ∆thres0 determines the parameter β in Eqn. (17). Combining the two conditions
above, we find the value for P (xˆ0) = 0.87± 0.003 which we can interpret as the probability
that the SNP has occurred when xˆ0 is below the threshold value that can trigger the canonical
pathway.
Moreover, having in Eqn. (12) also computed P (t2DM |CHD), we write the correspond-
ing likelihood
P (yˆ∗2|x∗2) =
1√
2pis2D
exp
[
−(yˆ
∗
2 − xˆ∗2)2
2s22D
]
. (42)
Note that we cannot follow a reasoning analogous to that for the case of the probability of
CHD because the population Nt2DM is not entirely random. Substituting yˆ
∗
2 = yˆ
∗
2(xˆ
∗
2) =
xˆ∗2/B2, where B2 is a function of the biochemical parameters, we find that
P (t2DM |CHD) = 1√
2pis2D
∫ µ2P−∆thres2
−∞
dxˆ∗2 exp
[
−(yˆ
∗
2 − xˆ∗2)2
2s22D
]
=
1
2
+
B2
2(1−B2) erf
[
(µ2P −∆thres2 )(1−B2)√
2s2DB2
]
. (43)
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We can now compute the posterior probability of the variable x2 given xˆ0, i.e.
P (xˆ∗2|xˆ0) =
1
2piσ0Dσ2P
1
P (xˆ0)
exp
[
−1
2
(
Γ− µ2eff
)]
exp
[
−(xˆ
∗
2 − µeff )2
2σ2eff
]
, (44)
finding for the probability that CHD will occur given that SPN has occurred that
P (CHD|SNP ) = 1
P (SNP )
∫ µ2P−∆thres2
−∞
dxˆ∗2 P (xˆ0|xˆ∗2) P (xˆ∗2)
=
1
2
+
1
2
erf
−σ20D∆thres2 + σ22P [A+ (µ2P −∆2)(A0 − A2)](A0 − A2)/A20√
2σ0Dσ2P
√
σ20P + σ
2
2P
(A0 − A2)2/A20
 . (45)
The variables in this formal expression are constrained by the relations found above and
which we summarize below:
P (SNP ) ≡ f00
(
x0, σ0D ;α
(k)
ij , β
)
= 0.30± 0.001 (46)
P (SNP |CHD) ≡ f02
(
x0, σ0D ,∆
thres
2 ;α
(k)
ij , β
)
= 0.20± 0.001 (47)
P (t2DM |CHD) ≡ f22
(
s2D ,∆
thres
2 ;α
(k)
ij , β
)
= 0.09± 0.001 . (48)
Here the subscript D indicates properties of the data as derived form the model and con-
strained by these particular data, and the subscript P indicates properties of the prior which
are based on the knowledge inferred from data sets delivered by other experiments. The
results in Eqns. (46) and (47) are of the same order as relative proportions found in other
studies, respectively in Ref. [4] and Refs. [3, 11]. The result in Eqn. (12) is a result of this
study.
These functions depend on our knowledge of the rates in the model of the implicated
pathways as well as on the statistical properties of the associated risk factor. However,
from these three relations as constrained by the data, we can solve for three parameters
only. Solving for the remaining parameters requires additional conditions for the statistical
properties of the priors and biochemical parameters. Nonetheless, the idea that the present
study serves to introduce and which we here applied to one data set on one risk factor has
been demonstrated, i.e. a) how to extract the statistical properties of the event from the
corresponding phenomenological data and then b) from the statistical properties of the event
how to extract biochemical information on the causal relations that link the event with the
risk factor.
IV. DISCUSSION
In this manuscript we derive the probability of occurrence of CHD based on data in the
presence of the SNP at the -308 position of the TNF-α gene. We first worked following a
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bottom-up approach. Comparing different hypotheses for the statistical relation between the
occurrences of SNP and CHD, we selected the working hypothesis on the basis of the Bayes
factors. We showed that the data favour (although without strong evidence) the association
of the SNP with the occurrence of CHD as well as the participation of the occurrence of
t2DM in the causal relation. Using the Bayes theorem, we computed the probability of the
SNP conditional on the occurrence of CHD. We then worked following a top-down approach.
We presented a schematic model for a simplistic description of the signalling pathway which
relates the presence of the SNP with the emergence of CHD. The data contain information on
equilibrium states of the several variables that describe the biochemical system and can thus
be translated into a probability description. We then computed the probability of CHD given
that the SNP had occurred, using for the likelihood the probability previously computed.
We expressed the result as a function of both the biochemical parameters of the model and
the statistical parameters of the prior probability distributions. Other probabilities were
also computed, which serve as constraints to the parameters.
In an upcoming study we will be exploring the idea further by integrating the sparse
existing data on various population samplings. We will select the data for CHD given
different risk factors, and for the SNP given different diseases. From the first selection we
intend to extract the remaining statistical parameters, since the prior of CHD will be shared.
Also a link should be established between this formalism and the CHD prediction estimates
from a multivariable risk calculation [30]. From the second selection we intend to extract the
biochemical parameters of the signalling pathway. Although the prior of CHD will be shared,
the biochemical system will grow in complexity and new rates will be introduced. We expect,
however, that by exhausting the data sets available we will reach a balance of unknowns and
equations that would allow us to solve the problem. Should this balance not be attained, we
will resort to determining confidence levels for the unknown parameters based on simulations
[18–20]. Whenever available, we will complement the study with temporal information to
obtain reaction rates [31]. Ultimately we expect to be able to infer a universal law for gene
mutation by systematising the various diseases into a comprehensive model of the signalling
pathway.
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Appendix A: Computation of the evidence
In this Appendix we compute the evidence for the six hypotheses discussed in Section II.
Hypothesis H00 has only one free parameter, the probability that the SNP occurred. This
probability, describing a mutation process, is assumed to have a Poisson distribution charac-
terized by the size of the population N and a mutation rate λ. The probability of n mutations
is
P (n|λ ∧N) = exp[−λN ] (λN)
n
n!
(A1)
with the mean number 〈n〉 = λN. For n = NSNP mutations in a sample of size N and a
uniform prior distribution for λ, P (λ) = 1, we find that
P (DSNP |H00) =
∫ ∞
0
dλ P (DSNP |λ ∧N)P (λ|H00)
=
∫ ∞
0
dλ exp [−λN ] (λN)
NSNP
NSNP !
=
1
N
. (A2)
Hypothesis H01 has two parameters, the probabilities that the SNP occurred given the two
values of the variable CHD. There are two possible sources of SNP, namely the population
with CHD and the population without CHD. The presence of the SNP follows a binomial
distribution where p01 is the frequency of the SNP for the case of CHD and p01¯ is the
frequency of the SNP for the case of CHD. It follows that
P (DSNP |H01) =
∫
dp01
∫
dp01¯ P (DSNP |p01 ∧ p01¯ ∧H01)P (p01 ∧ p01¯|H01)
=
∫
dp01 P (DSNP |p01 ∧H01)P (p01|H01)
+
∫
dp01¯ P (DSNP |p01¯ ∧H01)P (p01¯|H01) . (A3)
Moreover, assuming a uniform prior distribution probability for the frequencies p01 and p01¯
of the data on the SNP given respectively the occurrence or non-occurrence of CHD
P (p01|H01) = 1, P (p01¯|H01) = 1, (A4)
we find that
P (DSNP |H01) =
∫
dp01
(
NCHD
NSNP,CHD
)
p
NSNP,CHD
01 (1− p01)NSNP,CHD
+
∫
dp01¯
(
NCHD
NSNP,CHD
)
p
NSNP,CHD
01¯
(1− p01¯)NSNP,CHD
=
(
NCHD
NSNP,CHD
)
NSNP,CHD!NSNP,CHD!
(NCHD + 1)!
+
(
NCHD
NSNP,CHD
)
NSNP,CHD!NSNP,CHD!
(NCHD + 1)!
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=
1
NCHD + 1
+
1
NCHD + 1
. (A5)
Similarly to H01, hypothesis H10 has two parameters, the probabilities that the SNP
occurred given the two values of the variable t2DM. The evidence is given by the same
expression as that of hypothesis H01 with the variable CHD replaced by the variable t2DM
and under the analogous assumptions on the corresponding frequency priors p10 and p1¯0.
Hypothesis H11 has four parameters, one for each state of the variables CHD and t2DM.
This hypothesis combines the two hypotheses previously discussed which are assumed com-
plementary, thus being a case of a two-component hypothesis with probabilities β and (1−β)
[24]. It follows that
P (DSNP |H11) =
∫
dp01
∫
dp10
[
βP (DSNP |p01 ∧H11)P (p01|H11)
+(1− β)P (DSNP |p10 ∧H11)P (p10|H11)
]
+
∫
dp01¯
∫
dp1¯0
[
β˜P (DSNP |p01¯ ∧H11)P (p01¯|H11)
+(1− β˜)P (DSNP |p1¯0 ∧H11)P (p1¯0|H11)
]
(A6)
which yields
P (DSNP |H11) = β
(
NCHD
NSNP,CHD
)
NSNP,CHD!NSNP,CHD!
(NCHD + 1)!
+(1− β)
(
Nt2DM
NSNP,t2DM
)
NSNP,t2DM !NSNP,t2DM !
(Nt2DM + 1)!
+β˜
(
NCHD
NSNP,CHD
)
NSNP,CHD!NSNP,CHD!
(NCHD + 1)!
+(1− β˜)
(
Nt2DM
NSNP,t2DM
)
NSNP,t2DM !NSNP,t2DM !
(Nt2DM + 1)!
= β
1
NCHD + 1
+ (1− β) 1
Nt2DM + 1
+β˜
1
NCHD + 1
+ (1− β˜) 1
Nt2DM + 1
. (A7)
Here β = NCHD/(NCHD + Nt2DM) is the probability that the data were extracted from
the pool of hypothesis H01 and β˜ = NCHD/(2NCHD,t2DM + NCHD,t2DM + NCHD,t2DM) the
probability that the pool is that of the complement of H01. Similarly we define (1− β) and
(1− β˜) from hypothesis H10.
For Hypothesis Hchd11 we have four parameters for combined states of the variables CHD
and t2DM, namely CHD ∧ t2DM and CHD ∧ t2DM as the states which are conditional
to non-occurrence of t2DM, and t2DM ∧CHD and t2DM ∧CHD as the states which are
conditioned to occurrence of CHD. The corresponding four frequencies are as follows: p˜01
is the frequency of SNP given the occurrence of CHD and p˜01¯ the frequency of SNP given
non-occurrence of CHD, both subject to non-occurrence of t2DM; p˜11 is the frequency of
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SNP given that t2DM has occurred and p˜1¯1 the frequency of SNP given that t2DM has not
occurred, both subject to CHD having occurred. For a uniform prior probability of these
frequencies, we find that
P (DSNP |Hchd11 ) =
∫
dp˜01
∫
dp˜11
[
γP (DSNP |p˜01 ∧Hchd11 )P (p˜01|Hchd11 )
+(1− γ)P (DSNP |p˜11 ∧Hchd11 )P (p˜11|Hchd11 )
]
+
∫
dp˜01¯
∫
dp˜1¯1
[
γ˜P (DSNP |p˜01¯ ∧Hchd11 )P (p˜01¯|Hchd11 )
+(1− γ˜)P (DSNP |p˜1¯1 ∧Hchd11 )P (p˜1¯1|Hchd11 )
]
(A8)
which yields
P (DSNP |Hchd11 ) = γ
(
NCHD,t2DM
NSNP,CHD,t2DM
)
NSNP,CHD,t2DM !NSNP,CHD,t2DM !(
NCHD,t2DM + 1
)
!
+(1− γ)
(
NCHD,t2DM
NSNP,CHD,t2DM
)
NSNP,CHD,t2DM !NSNP,CHD,t2DM !
(NCHD,t2DM + 1)!
+γ˜
(
NCHD,t2DM
NSNP,CHD,t2DM
)
NSNP,CHD,t2DM !NSNP,CHD,t2DM !(
NCHD,t2DM + 1
)
!
+(1− γ˜)
(
NCHD,t2DM
NSNP,CHD,t2DM
)
NSNP,CHD,t2DM !NSNP,CHD,t2DM !(
NCHD,t2DM + 1
)
!
= γ
1
NCHD,t2DM + 1
+ (1− γ) 1
NCHD,t2DM + 1
+γ˜
1
NCHD,t2DM + 1
+ (1− γ˜) 1
NCHD,t2DM + 1
. (A9)
Here γ = NCHD,t2DM/NCHD and γ˜ = NCHD,t2DM/Nt2DM .
Similarly to H
(chd)
11 , hypothesis H
(t2dm)
11 has four parameters for combined states of the
variables CHD and t2DM, namely t2DM ∧ CHD and t2DM ∧ CHD as the states con-
ditional on non-occurrence of CHD, and CHD ∧ t2DM and CHD ∧ t2DM as the states
conditional on occurrence of t2DM. The frequencies are analogously defined to those of hy-
pothesis H
(chd)
11 . The evidence is given by the same expression as that of hypothesis H
(chd)
11
with p˜01 and p˜01¯ replaced by the frequency of SNP, subject to non-occurrence of CHD, given
the occurrence or non-occurrence of t2DM respectively p˜10 and p˜1¯0, and p˜1¯1 replaced by p˜11¯.
Analogously γ is replaced by NCHD,t2DM/Nt2DM and γ˜ by NCHD,t2DM/NCHD.
Appendix B: Calculation of P (SNP |H00)
In this Appendix we compute for the purpose of comparison the probability of occurrence
of SNP for hypothesis H00. Starting from Eqn. (A1) and using the Bayes theorem, we find
for the posterior probability of λ that
P (λ|DSNP ∧N) = P (DSNP |λ ∧N)P (λ|N)
P (DSNP |N) . (B1)
20
The normalizing constant is the evidence computed in Eqn. (A2). Given the data and for
P (SNP |λ ∧H00) = λ, the probability of a mutation in a population of size N is
P (SNP |H00) =
∫
dλ P (SNP |λ ∧H00)P (λ|DSNP ∧H00)
=
∫
dλ λN exp [−λN ] (λN)
NSNP
NSNP !
=
NSNP + 1
N
(B2)
which for NSNP = 184 and N = 683 yields P (SNP ∧H00) = 0.27. Despite the small
difference between the values derived from the two hypotheses (which might be considered
insignificant given the observational errors which are of order 1/
√
N ≈ 0.038), the fact that
there is a difference highlights the relevance of hypothesis testing before committing to a
probability which will act as likelihood in subsequent calculations.
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